pharma-and-clinical-pharmacy-congress-2016_posters

19 / 21

Page 70
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Design, synthesis and biological evaluation of novel 2-phenyl-1-benzopyran-4-one derivatives as
potential poly-functional anti-Alzheimer’s agents
Manjinder Singh and Om Silakari
Punjabi University, India
Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex
etiology of Alzheimer’s disease (AD). Following this approach, a new series of 2-phenyl-1-benzopyran-4-one derivatives
were designed, synthesized and biologically evaluated as inhibitors of acetylcholinesterases (AChEs), advanced glycation end
products formation (AGEs) and also for their radical scavenging activity. The in vitro studies showed that the majority of
synthesized derivatives inhibited acetylcholinesterase (AChE) with IC50 values in the low-micromolar range. Among them,
inhibitors 7h, 7k and 7a, strongly inhibited AChE, with IC50 value of 6.33, 7.56 and 11.0 nM, respectively, and were more potent
than the reference compound donepezil. Moreover, the molecular docking study displayed that most potent compounds
simultaneously bind to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater
ability to inhibit advanced glycation end products formation with additional radical scavenging property. Thus, 2-phenyl-1-
benzopyran-4-one derivatives might be the promising lead compound as potential poly-functional anti-Alzheimer’s agents.
Assessment of adhesion response to 3D printed materials for ophthalmic device development
Alband M, Lee Rmh, Penny M, Brocchini S and Hilton S
University College London, UK
Introduction&Aim:Glaucoma is the leading cause of irreversible visual impairment worldwide. Glaucoma surgical devices fail
due to a scarring response that resulted in fibrous encapsulation surrounding the device preventing aqueous humor drainage.
3D printing technology has the potential to develop personalized ophthalmic devices or organs with improved cost effectiveness
and productivity. Limited experimental data exists as to the biocompatibility response of 3D printed photopolymers. We
performed cell adhesion and protein adsorption studies of 3D printed photopolymers compared to materials used in current
ophthalmic devices (silicone, polytetrafluoroethylene (PTFE) and poly (methyl methacrylate) (PMMA)) to assess 3D printed
materials as a potential route for ophthalmic device development.
Methods: 3D printed materials (n=6) were developed using a high-resolution, desktop stereo-lithography (SLA) 3D printer
and compared to materials used in current ophthalmic devices. Protein adsorption was quantified using a micro bicinchoninic
acid (micro BCA) assay and fluorescein-conjugated bovine serum albumin (FITC-BSA) adsorption. Cell adhesion (monocytes,
fibroblasts) was assessed using alamarBlue, CyQUANT and Live/Dead assays. Data were compared using a two-tailed unpaired
t-test.
Results: 3D printed materials demonstrated low cell adhesion and protein adsorption. Results were similar to those found
with materials used in current ophthalmic devices (P>0.05). However, it was noted that 3D printed materials demonstrated
increased cytotoxicity (P<0.05).
Conclusion: 3D printed photopolymer materials demonstrated a similar biocompatibility response to currently used materials
and may allow for the development of customizable ophthalmic devices or organs. Subsequent testing will determine the
adhesion response to 3D printed materials containing anti-scarring agents.